Physician profile

Indra Bole

Advanced Heart Failure and Transplant Cardiology · Dublin, OH

NPI 1518306885

$25,455.09

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Travel and Lodging$827.79
Food and Beverage$415.88

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbott Laboratories $12,534.18 2019-2023 Thoratec Heartmate 3 Lvas Implant Kit
Medtronic Vascular, INC. $11,250.00 2020
One Lambda, INC. $1,110.03 2024
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $393.53 2019-2020
Astrazeneca Pharmaceuticals Lp $54.84 2020
Procyrion, INC. $41.06 2024
Zoll Circulation INC $35.32 2021
Amgen INC. $20.38 2019
Pfizer INC. $15.75 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Indra Bole

$25,455.09

in general payments reported 2019-2025

Years
2019-2024
Top company
Abbott Laboratories

https://glasscript.com/doctor/719909/indra-bole

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.